Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY (MRK)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Most relevant news about MERCK AND COMPANY
11:11aMERCK AND : FDA restricts Keytruda, Tecentriq monotherapy
AQ
06/21MERCK AND : - Late-Breaking Data to be presented from the Comparative Trials wit..
AQ
06/21MERCK AND : CEO Kenneth Frazier, speaking in Philly, urges people to call out 'u..
AQ
06/20Latecomer Sanofi looks to catch next wave of cancer therapies
RE
06/18MERCK AND : Late-Breaking Data to be Presented from the Comparative Trials with ..
PU
06/18BRISTOL MYERS SQUIBB : BMS scores China's first IO approval
AQ
06/15MERCK AND : FDA Grants Priority Review to Merck's Supplemental Biologics License..
AQ
06/15MERCK AND : FDA Approves Merck's KEYTRUDA for Treatment of Refractory or Relapse..
AQ
06/14MERCK AND : FDA Approves Merck's KEYTRUDA for Previously Treated Patients with R..
AQ
06/14MERCK AND COMPANY : Ex-dividend day for
FA
06/13MERCK AND : FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Treatment o..
BU
06/13MERCK AND : Gets FDA Priority Review for Expanded Gardasil Age Range
DJ
06/13MERCK AND : FDA Grants Priority Review to Merck’s Supplemental Biologics L..
BU
06/13Sanofi says on track to regain solid position in cancer drugs
RE
06/13AGILENT TECHNOLOGIES : Companion Diagnostic Gains Expanded FDA Approval in Cervi..
AQ
More most relevant news
All news about MERCK AND COMPANY
11:11aMERCK AND : FDA restricts Keytruda, Tecentriq monotherapy
AQ
06/21AGILENT TECHNOLOGIES : Companion Diagnostic Gains Expanded FDA Approval in Cervi..
AQ
06/21MERCK AND : - Late-Breaking Data to be presented from the Comparative Trials wit..
AQ
06/21MERCK AND : CEO Kenneth Frazier, speaking in Philly, urges people to call out 'u..
AQ
06/20Latecomer Sanofi looks to catch next wave of cancer therapies
RE
06/18MERCK AND : Late-Breaking Data to be Presented from the Comparative Trials with ..
PU
06/18BRISTOL MYERS SQUIBB : BMS scores China's first IO approval
AQ
06/15MERCK AND : Modern Alchemists Are Making Chemistry Greener
AQ
06/15MERCK AND : `s Keytruda snags I-O`s first cervical cancer nod to back up HPV fig..
AQ
06/15MERCK AND : FDA Grants Priority Review to Merck's Supplemental Biologics License..
AQ
More news
Sector news : Pharmaceuticals - NEC
11:16aSHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
07:38aRoche to Appoint James Sabry as Head of Partnering
DJ
06/21LONDON MARKETS: FTSE 100 Drops As Oil Shares Extend Losses; Pound Rallies On ..
DJ
06/21Canada sets October start for legal recreational marijuana sales
RE
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
06/20Roche to Buy Rest of Cancer Firm -- WSJ
DJ
More sector news : Pharmaceuticals - NEC
Official Publications
05/25Report 
05/24SEC Filing 8K 
05/15Report 
05/04Report 
05/02Report 
05/02SEC Filing 8K 
More official Publications
News from SeekingAlpha
06/21Key events next week - healthcare 
06/21Neon Therapeutics Firms Its Plan For $100 Million IPO 
06/19ALZHEIMER'S DISEASE : A History Of Drug Failures 
06/173 THINGS IN BIOTECH, JUNE 16 : Do You Know Anything About EHA? 
06/16Dynavax Gives A Welcome Business Update 
06/163 THINGS IN BIOTECH, JUNE 15 : Keep Rolling, Pembro 
Latest Tweets
10:43aAdam H. Schechter Sells 134,094 Shares of Merck & Co., Inc. $MRK Stock  
07:27aInvestors Sell Shares of Merck & Co., Inc. $MRK on Strength Following Ins.. 
03:56aDow Jones Analysis Video - $DJIA $DIA $SDOW $XOM $GE $GS $MRK $PFE $BMY $VZ .. 
06/21These guys are good -- Novo Nordisk’s ‘sema’ whips Merck’s diabetes drug riva..
3
06/2110+ yrs ago when Lux helped scientists + entrepreneurs start breakthrough vac..
5
More tweets
Qtime:331
Financials ($)
Sales 2018 42 072 M
EBIT 2018 13 566 M
Net income 2018 7 224 M
Debt 2018 15 754 M
Yield 2018 3,19%
P/E ratio 2018 23,55
P/E ratio 2019 15,92
EV / Sales 2018 4,29x
EV / Sales 2019 4,09x
Capitalization 165 B
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 69,1 $
Spread / Average Target 13%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
Leslie A. Brun Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY8.90%164 862
JOHNSON & JOHNSON-12.27%328 751
PFIZER0.00%211 871
NOVARTIS-10.17%188 057
ROCHE HOLDING LTD.-12.19%183 625
AMGEN7.07%123 203